falsefalse

Evolving Treatment Strategies in High-Risk Neuroblastoma - Episode 8

Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials

,

Drs Sholler and Agrawal detail recent studies on naxitamab and dinutuximab demonstrating effectiveness in treating recurrent or refractory neuroblastoma, leading to their FDA approvals, and significantly influencing treatment practices.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: An Overview of Neuroblastoma
    EP. 2: Approaches to Diagnosing Neuroblastoma
    EP. 3: Role of CURIE Scores in the Treatment and Management of Neuroblastoma
    EP. 4: Current Treatment Paradigm for Newly Diagnosed Neuroblastoma
    EP. 5: Differentiating Refractory and Relapsed Neuroblastoma
    EP. 6: Updated Data From the LEAHRN Study in High-Risk Neuroblastoma
    EP. 7: Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)
    Now Viewing
    EP. 8: Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials
    EP. 9: Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R
    EP. 10: Future Perspectives in the Treatment of Neuroblastoma

    Related Content:

    Evolving Treatment Strategies in High-Risk NeuroblastomaOncLive News Network®
    Novel Treatment Approaches Under Investigation in ROS1+ NSCLC
    Another FDA-Approved Option? The Potential Role for Taletrectinib in ROS1+ NSCLC
    Pooled Data for Taletrectinib in ROS1+ NSCLC
    x